TG Therapeutics, Inc. $TGTX Stock: Trust Co of the South Raises Position

Trust Co of the South boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 229.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,298 shares of the biopharmaceutical company’s stock after purchasing an additional 17,623 shares during the quarter. Trust Co of the South’s holdings in TG Therapeutics were worth $1,411,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its stake in shares of TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares during the period. Farther Finance Advisors LLC grew its position in shares of TG Therapeutics by 45.8% during the third quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 312 shares in the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of TG Therapeutics during the second quarter worth about $96,000. Pingora Partners LLC acquired a new position in shares of TG Therapeutics during the second quarter worth about $121,000. Finally, Allworth Financial LP acquired a new position in shares of TG Therapeutics during the second quarter worth about $128,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Bank of America boosted their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Finally, B. Riley Financial boosted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $63.00.

Insider Activity

In other news, Director Laurence Charney sold 5,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the transaction, the director owned 168,640 shares in the company, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.87% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $53.16 on Friday. The firm has a market capitalization of $8.14 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 2.25 and a beta of 1.80. The business’s fifty day moving average price is $54.62 and its 200 day moving average price is $48.80. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The firm’s quarterly revenue was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 earnings per share. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.